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ABSTRACT
Trastuzumab-induced cardiotoxicity (TIC) is the primary adverse event that 
limits the use of trastuzumab in HER2-positive breast cancer patients. However, the 
incidence and risk factors of TIC in HER2-positive gastric cancer are not known. 
Therefore, we evaluated the incidence and predictive factors of TIC in gastric cancer 
patients treated with trastuzumab in clinical practice. We reviewed cardiac dysfunction 
in HER2-positive gastric cancer patients between December 2005 and April 2015 in 
a prospectively-collected database that included prospective clinical trials at Yonsei 
Cancer Center, Republic of Korea. TIC was defined as an absolute decline in left 
ventricular ejection fraction (LVEF) of at least 10 percentage points from the baseline 
to a value less than 55%, as identified by a multiple-gated acquisition scan or an 
echocardiogram. Among the 115 patients, 70 patients (60.9%) received trastuzumab 
combined with chemotherapy, and 45 patients (39.1%) received chemotherapy 
alone as a first-line therapy. Symptomatic heart failure was not observed in either 
group, but a significant asymptomatic drop in LVEF was noted in five (7.1%) of the 
trastuzumab combined-group patients and in one (2.2%) chemotherapy-only group 
patient [hazard ratio (HR), 3.47; 95% confidence interval (CI), 0.40–29.8; P=0.257]. 
TIC was observed more frequently in elderly patients than in younger patients (HR, 
per age in year, 1.16; 95% CI, 1.02–1.31; P=0.019). Similar to prior observations in 
breast cancer, TIC in gastric cancer patients is not frequent or reversible. However, 
the asymptomatic drop in LVEF should be monitored continually in HER2-positive 
gastric cancer patients treated with trastuzumab, especially in elderly patients.
INTRODUCTION
HER2 (ErbB2 or HER-2/neu) belongs to the human 
epidermal growth factor receptor (HER) family and is 
significantly correlated with the proliferation, migration, 
and differentiation of many kinds of cancer cells through 
its involvement in the activation of the PI3K/Akt and Ras/
Raf/MEK/MAPK pathways. The monoclonal antibody 
trastuzumab, which targets HER2, is a well-known HER2-
directed therapeutic drug [1]. This agent demonstrated 
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improved survival outcomes in cancer patients, especially 
in cases of breast cancer associated with the amplification 
of HER2 and/or overexpression of HER2 at the messenger 
RNA or protein level [2-4].
Meanwhile, because preclinical trastuzumab studies 
suggest that ErbB2 plays an essential role in the developing 
embryonic heart and is important for maintaining cardiac 
function in the adult heart [5], there are considerable 
concerns regarding cardiotoxicity in early clinical trials 
[2]. Although the primary risk for trastuzumab-induced 
cardiomyopathy (TIC) is reportedly the combination with 
anthracycline, trastuzumab without anthracycline also 
causes a reversible drop in left ventricular ejection fraction 
(LVEF) in 3.04–10.4% of incidence [6-10].
In gastric cancer, the Trastuzumab for Gastric Cancer 
(ToGA) trial investigated the efficacy of trastuzumab in 
HER2-positive metastatic gastric cancer patients. Though 
a low incidence of cardiotoxicity was found in this study 
(5% in the trastuzumab plus chemotherapy group and 1% 
in the chemotherapy group) [11], detailed profiles regarding 
LVEF in the treatment groups were not reported. Due to 
the lack of clinical trials and knowledge, the incidence and 
characteristics of cardiotoxicity related to trastuzumab in 
gastric cancer patients have not been clearly shown.
In this study, we tried to evaluate the incidence, 
characteristics, and clinical factors that were potentially 
related to TIC in patients with gastric cancer.
RESULTS
Patients characteristics
Between January 2006 and April 2015, we collected 
clinicopathological data from 115 patients who were 
diagnosed with inoperable, locally advanced, recurrent, 
or metastatic HER2-positive gastric cancer patients, and 
from participants in trastuzumab clinical trials at the Yonsei 
Cancer Center [NCT01041404 (ToGA trial), NCT01736410, 
and NCT0140696]. Among the patients, 70 received 
chemotherapy in combination with trastuzumab as a first-line 
treatment, whereas 45 were treated with chemotherapy only. 
Table 1  provides the baseline characteristics of the patients. 
Eighty-six patients (74.8%) were male and the median age 
at diagnosis was 58 (range, 30–80). Most of the clinical 
features were similar between the two groups. Of the four 
patients with underlying cardiac disease, one patient had 
persistent, asymptomatic atrial fibrillation, and the other three 
patients had coronary arterial diseases that were treated by 
percutaneous coronary intervention.
Treatment and changes in LVEF
The median baseline LVEF of all the patients was 
66% (range, 57–75), and the median number of times 
LVEF measurements conducted was 4 (range, 2–21). For 
all patients included in this study, the median interval of 
cardiac monitoring was 12.0 weeks (range, 3.3–27.4). The 
median trastuzumab dose administered to the 70 patients 
who received both the drug and chemotherapy was 56 mg/
kg (range, 8-374) over a median number of 9 cycles (range, 
1–62) and a median of 6.4 months (range, 0.7–47.3). The 45 
patients who were treated with chemotherapy-only received 
a median of 8 cycles (range, 2–92) of chemotherapy over 5.6 
months (range, 0.5–65.2). The median follow-up duration 
was 58.2 months (95% CI, 49.6–67.2). As of November 30, 
2015, 69 out of 115 patients (60.0%) experienced a drop 
in LVEF. The median percentage points of the decrease 
in LVEF from baseline was 6 (range, 1–19). Among the 
patients who experienced a drop in LVEF, six patients (five 
in the trastuzumab group, one in the chemotherapy only 
group) experienced a significant asymptomatic drop in 
LVEF of a median 11.5 percentage points (range, 10–19) 
from baseline LVEF.
Cardiac dysfunction in the patients according to 
treatment with trastuzumab
In the patients who were treated with trastuzumab, 
62.9% (44/70) experienced some degree of decline in LVEF, 
but the decreases were not significantly higher compared 
with patients treated with chemotherapy only [55.6% (25/45); 
P=0.435]. The median time to reach to maximal decreases in 
LVEF from the baseline LVEF measurement was 5.3 months 
(range, 1.4–30.4). However, no symptomatic congestive 
heart failure (CHF) or cardiac deaths occurred in the patients 
treated with or without trastuzumab.
According to the definition described above, the 
incidence of TIC was 7.1% (5/70). The cumulative 
incidence of cardiac dysfunction was not different 
in the trastuzumab-treated group compared with the 
chemotherapy- only group (HR, 3.47; 95% CI, 0.40–29.8; 
P=0.257; Figure 1). No case occurred between 1 and 3 
months from the last dose of trastuzumab.
Clinical course of the patients with TIC
There were five patients with TIC (Case#1, Case#2, 
Case#3, Case#4, and Case#5) (Figure 2).
Case#1 (73-year-old male patient) experienced a 
significant asymptomatic drop in LVEF of 19 percentage 
points to 51% at week 73, after the 24th treatment cycle 
of trastuzumab maintenance followed by capecitabine plus 
cisplatin combined with trastuzumab. Because the protocol 
called for treatment to be continued when LVEF ≥ 45%, 
the patient continued treatment with trastuzumab and LVEF 
recovered to 65% at week 83. Case#2 (69-year-old male 
patient) presented with a significant asymptomatic drop 
in LVEF of 10 percentage points to 50% at week 29 after 
the 7th cycle of treatment with trastuzumab combined with 
5-FU and cisplatin. The patient continued the same dose 
of trastuzumab plus 5-FU but omitted cisplatin because 
of general weakness, and LVEF recovered to 56% at 
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Table 1: Baseline characteristics of each treatment group
Variable CTX only Trastuzumab + 
CTX
Total P-value
Number of patients 45 70 115
Gender
Male 34 75.6% 52 74.3% 86 74.8% 0.878
Female 11 24.4% 18 25.7% 29 25.2%
Age
Median age, years (range) 58 (37–72) 59 (30–80) 58 (30–80) 0.884*
BMI
Median, kg/m2 (range) 22.7 (16.7–35.0) 21.4 (13.8–32.5) 21.9 (13.8–35.0) 0.059*
Baseline LVEF
Median, % (range) 66 (57–75) 65 (57–75) 66 (57–75) 0.307*
Maximally decreased LVEF from baseline LVEF
Median, % (range) 6 (1–12) 7 (1–21) 6 (1–21) 0.279*
Total treatment cycles
Median, number (range) 8 (2–92) 9 (1–62) 8 (1–92) 0.827*
Hypertension
Yes 12 26.7% 18 25.7% 30 26.1% 0.910
No 33 73.3% 52 74.3% 85 73.9%
Underlying cardiac disease
Yes 1 2.2% 3 4.3% 4 3.5% >0.99†
No 44 97.8% 67 95.7% 111 96.5%
Diabetes
Yes 5 11.1% 8 11.4% 13 11.3% >0.99†
No 40 88.9% 62 88.6% 102 88.7%
Hyperlipidemia
Yes 0 0.0% 2 2.8% 2 1.7% 0.519†
No 45 100% 68 97.2% 113 98.3%
Cerebrovascular disease
Yes 1 2.2% 3 4.3% 4 3.5% >0.99†
No 44 97.8% 67 95.7% 111 96.5%
Smoking
Current 15 33.3% 20 28.6% 35 30.4% 0.862
Former 11 24.4% 18 25.7% 29 25.2%
Never 19 42.3% 32 45.7% 51 44.4%
BMI, body mass index; CTX, cytotoxic chemotherapy; LVEF, left ventricular ejection fraction; *Analyzed by the Mann-
Whitney U test; † Analyzed by the Fisher’s exact test
Oncotarget61840www.impactjournals.com/oncotarget
week 36. Case#3 (56-year-old male patient) presented with 
a significant asymptomatic drop in LVEF of 14 percentage 
points to 53% at week 27 after 8 cycles of trastuzumab 
treatment combined with capecitabine and cisplatin. The 
patient stopped the treatment due to cancer progression 
at week 28. A follow-up cardiac evaluation could not be 
performed because the patient rapidly progressed and 
succumbed to cancer. Case#4 (74-year-old female patient) 
exhibited a significant asymptomatic drop in LVEF from 
65% to 54% at week 38 after 9 cycles of trastuzumab 
monotherapy following 6 cycles of combination therapy 
with trastuzumab, 5-FU, and cisplatin. The patient changed 
her regimen due to disease progression, and a follow-up 
test was not performed. Case#5 (80-year-old male patient) 
presented with a significant, asymptomatic drop in LVEF 
of 17 percentage points to 52% at week 26 after 8 cycles 
of trastuzumab combined with 5-FU and cisplatin. Because 
the patient succumbed to the cancer, subsequent cardiac 
evaluation could not be conducted.
Clinical factors related to TIC
We compared clinical factors according to the 
occurrence of cardiac dysfunction separately in the 
trastuzumab-treated group. The median number of cycles 
of trastuzumab was 10 (range, 8–38) in the patients with 
cardiac dysfunction, which was not different compared to 
patients without cardiac dysfunction (median, 8; range, 
1–62; P=0.403). None of the patients with underlying 
cardiac disease experienced TIC. Among the clinical 
factors possibly related to trastuzumab-induced cardiac 
dysfunction, aging was the only significant factor to affect 
the occurrence of TIC (Table 2; HR, per age in year, 1.16; 
95% CI, 1.02–1.31; P=0.019).
Figure 1: Cumulative incidence of asymptomatic drop in LVEF in both groups.
Figure 2: Clinical course of four patients who experienced an asymptomatic drop in LVEF. The hollow dots indicate LVEF 
as the time progressed from the start of treatment. Filled dots indicate the occurrence of a significant drop in LVEF.
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DISCUSSION
In the present study, we assessed the incidence of 
cardiac dysfunction in HER2-positive gastric cancer 
patients who were treated with cytotoxic chemotherapy in 
combination with trastuzumab. The incidence of TIC was 
7.1%, which was not higher than the incidence in patients 
treated with chemotherapy only. The only clinical factor 
possibly related to cardiotoxicity was age greater than 
70 years.
Cardiotoxicity is one of the well-known toxicities 
caused by trastuzumab. In contrast to myocardial injury 
induced by anthracycline, cardiotoxicity induced by 
trastuzumab was thought to be generally reversible 
by the discontinuation of trastuzumab administration 
and not dose-dependent or functionally related to the 
contractile elements of the heart [12]. The incidence 
Table 2: Cox regression models1 for the incidence of TIC2 by risk factors
Variables Number of Patients Incidence HR 95% CI for HR P-Value
No %
Median (range) for 
continuous variables
Age (years) 59 (30–80) 1.16 1.03–1.31 0.019
Gender
Male 52 4 7.7 1.49 0.17–13.4 0.722
Female 18 1 5.6 1
BMI (kg/m2) 21.4 (13.8–32.5) 0.94 0.69–1.28 0.701
Hypertension
Yes 18 2 11.1 1.74 0.29–10.5 0.545
No 52 3 5.8 1
Diabetes
Yes 8 0 0 N/A N/A
No 62 5 8.1
Smoking
Current/Former 38 0 0 N/A N/A
Never 32 5 15.6
Baseline LVEF (%)
≥55 and ≤60 20 1 5.0 1.60 0.18–14.3 0.677
≥60 50 4 8.0 1
Baseline serum CRP (mg/L) 13.3 (0–201) 1.00 0.98–1.02 0.799
Total cholesterol (mg/dL) 153.5 (74–343) 1.00 0.99–1.02 0.769
Cycle (number) 9 (1–62) 0.99 0.92–1.08 0.844
Cumulative dose (mg/kg) 56 (8–374) 1.00 0.98–1.02 0.927
Combined cytotoxic chemotherapy
FP 31 4 12.9 6.74 0.74–61.6 0.091
SP/XP 39 1 2.6 1
BMI, body mass index; CRP, C-reactive protein; FP, fluorouracil plus cisplatin chemotherapy; HR, hazard ratio; LVEF, 
left ventricular ejection fraction; SP, TS-1 plus cisplatin chemotherapy; TIC, trastuzumab-induced cardiotoxicity; XP, 
capecitabine plus cisplatin chemotherapy; 1trastuzumab treatment group only; N=70; 2TIC was defined as at least one of the 
following: decreased LVEF ≥10% points to a value of <55%, severe congestive heart failure, or cardiac death.
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of cardiotoxicity was approximately 0.4–4.0% in CHF 
and 4.1–10.4% in left ventricular dysfunction in a large-
scale adjuvant trastuzumab breast cancer trial [12]. In a 
pivotal study reported by Slamon et al., the metastatic 
breast cancer patients who received the concurrent 
treatment of trastuzumab and anthracycline had a high 
incidence of cardiotoxicity that accounted for 27% of 
symptomatic or asymptomatic cardiac dysfunction [2]. 
The incidence of TIC was also influenced by exposure 
to anthracycline [13].
As anti-HER2 therapeutic agents were administered 
to HER2-positive gastric cancer patients, cardiac safety 
was also carefully considered, similarly to breast cancer. 
However, several clinical factors possibly related to 
cardiotoxicity in breast cancer patients, including obesity 
[6], previous exposure to anthracycline [7], and radiation 
to the chest [7], are not frequently found in gastric cancer 
patients. Additionally, gastric cancer patients include 
a greater number of males, the elderly, and members of 
the Asian population, compared to breast cancer patients. 
Therefore, the cardiotoxicity profiles of HER2-positive 
gastric cancer patients treated with trastuzumab are likely 
different from breast cancer patients.
Despite its rarity in the clinical trials conducted 
thus far in the patients with HER2-positive gastric 
cancer, the cardiotoxicity induced by trastuzumab 
was infrequent, reversible, and not severe, similar to 
observations in breast cancer. The rate of all cardiac 
adverse events, grade 3 or 4 cardiac adverse events and 
a significant drop in LVEF to an absolute value <50% 
were 6%, 1%, and 5%, respectively, in the trastuzumab 
and chemotherapy combination group in the ToGA trial 
[11]. A phase II clinical trial of trastuzumab, combined 
with TS-1 and cisplatin, reported that half of the patients 
(15/30) experienced a decline in LVEF from baseline 
during the treatment, and six patients (20%) presented 
with a >10% drop in LVEF from baseline values [14]. 
In addition, a retrospective study indicated that 26% 
of the HER2-positive metastatic esophagogastric 
cancer patients treated with trastuzumab experienced 
asymptomatic cardiotoxicity (defined as a drop of more 
than 10% in LVEF in the third-month echocardiogram) 
and 8.6% experienced symptomatic cardiotoxicity [15] 
(Supplementary Table 1).
In the present study, during a median 9.3 month 
(range, 3.5–68.2) follow-up period, we found a significant 
asymptomatic drop in LVEF in 7.1% of the gastric 
cancer patients treated with a trastuzumab combination. 
There was no symptomatic cardiac dysfunction related to 
trastuzumab. Considering that the median progression-
free survival time of the patients who were treated with 
a trastuzumab combination therapy in the ToGA trial was 
6.7 months, the patients with inoperable or metastatic 
HER2-positive gastric cancer were expected to receive 
trastuzumab for approximately 6–7 months. In this study, 
the rough incidence of a significant asymptomatic drop in 
LVEF at 7 months was 5.1% in the trastuzumab-treated 
group and 2.7% in chemotherapy-only group (P=0.227). 
Most of the significant, asymptomatic drops in LVEF 
were reversible within 6 weeks of the discontinuation of 
trastuzumab, or within 8 weeks despite the continuation of 
trastuzumab. Therefore, we believed that the differential 
diagnosis of another cardiac disease was required for the 
patients with persistently decreased LVEF.
Although 78 deaths occurred, none were related to 
TIC, and one patient experienced stable angina pectoris 
8 months after the discontinuation of trastuzumab. In 
addition, either overall survival (HR, 0.936; 95% CI, 
0.290–3.023; P=0.912) or progression free survival 
(HR, 0.875; 95% CI, 0.350–2.186; P=0.775) was 
different in the patients with TIC compared with those 
without TIC.
The analysis of clinical factors related to cardiac 
dysfunction revealed that old age was a possible risk 
factor for TIC in inoperable or metastatic HER2-positive 
gastric cancer patients (Table 2). Other possible risk 
factors, including baseline LVEF lower than 60%, chronic 
diseases, and smoking history were not statistically 
significant. As well, although we analyzed the correlation 
between serum C-reactive protein (CRP), a classic 
biomarker for heart failure [16], and total cholesterol, 
another classic biomarker for cardiovascular disease 
[17], we did not detect a significant association (Table 
2). However, these results are very preliminary due to the 
small number of cases.
The major limitations of our study were its 
small number of patients, the introduction of a 
potential selection bias because not all of the patients 
were included in the analyses, and heterogeneous 
therapeutic regimens. Due to a lack in the number 
of events, the evaluation of several clinical factors 
that might have been related to cardiotoxicity was 
insufficient. Moreover, only 33 patients had a baseline 
and follow-up results evaluated by echocardiogram 
and several parameters for diastolic dysfunction could 
not be fully analyzed. As well, other cardiac markers, 
including high-sensitivity C-reactive protein (hs-CRP) 
and B-type natriuretic peptide (BNP), were also not 
evaluated. Despite these limitations, the significance 
of this report included showing the frequency and 
detailed characteristics of cardiac dysfunction caused 
by trastuzumab in gastric cancer patients from 
prospectively-collected databases.
It was generally accepted that TIC was infrequent 
and reversible. However, a lack of knowledge regarding 
TIC in patients with gastric cancer remains, and 
we are not yet able to predict the long-term cardiac 
consequences of trastuzumab [18]. Awareness and 
continuous observation of cardiac events in HER2-
positive gastric cancer patients receiving anti-HER2 





Patients who were diagnosed with HER2-positive 
gastric cancer between December 2005 and April 2015 at 
the Yonsei Cancer Center, Seoul, Republic of Korea were 
included in this study. The criteria for eligibility were as 
follows: 1) histologically proven HER2-positive, advanced 
gastric cancer; 2) age ≥ 18 years; 3) inoperable locally 
advanced, recurrent, or metastatic disease; 4) an Eastern 
Cooperative Oncology Group (ECOG) performance 
status of 0–2; 5) adequate cardiac function [LVEF ≥ 
55% measured by echocardiography or a multiple-gated 
acquisition (MUGA) scan]; and 6) at least one follow-up 
echocardiography or MUGA scan test during the first-line 
treatment (whether or not the regimen included anti-HER2 
treatment).
The exclusion criteria were as follows: 1) 
operable gastric cancer; 2) the presence of other active 
malignancies; 3) treatment with other anti-HER2 target 
agents including lapatinib or trastuzumab emtansine; 4) 
clinically severe cardiac problems [including documented 
CHF, uncontrolled coronary artery disease (angina pectoris 
requiring antianginal medication or transmural infarction 
on electrocardiography (ECG)], uncontrolled hypertension 
(systolic blood pressure > 180 mmHg or diastolic > 100 
mmHg), high risk arrhythmias, or significant valvular 
disease; or 5) the presence of other severe medical 
illnesses.
HER2 positivity was defined using the HER2 
scoring criteria for gastric cancers by Hofmann et al. 
[19] and was confirmed using immunohistochemical 
staining (IHC; Hercep Test, Dako, Denmark) or silver 
in situ hybridization (SISH; Ventana Discovery XT 
system, Ventana/Roche, United States) by experienced 
pathologists at the Yonsei Cancer Center.
Clinical information, including gender, age, body 
mass index (BMI), baseline LVEF, underlying chronic 
diseases, and smoking history, was reviewed and 
documented.
The ethical principles for medical research 
established by the World Medical Association Declaration 
of Helsinki were followed throughout the study. The 
Severance Hospital, Seoul, Korea Institutional Review 
Board reviewed and approved this study (IRB approval 
number: 2014-2763-001)
Treatment
This study included HER2-positive advanced 
or metastatic gastric cancer patients who received 
chemotherapy with or without trastuzumab not only in 
clinical practice and clinical trials. The patients were 
treated with one of the following first-line treatment 
regimens: trastuzumab treatment regimens including 
trastuzumab in combination with fluorouracil (5-FU) plus 
cisplatin, trastuzumab in combination with capecitabine 
plus cisplatin [11], or trastuzumab in combination with 
S-1 plus cisplatin [14]. All of the therapeutic regimens 
that included trastuzumab involved the intravenous 
infusion of trastuzumab at a dose of 8 mg/kg on day 1 of 
the first cycle, followed by 6 mg/kg every 3 weeks until 
disease progression. Chemotherapeutic regimens without 
anti-HER2-targeted therapy included 5-FU plus cisplatin, 
capecitabine plus cisplatin, or TS-1 plus cisplatin. The 
regimens used for the patients in this study were the same 
as those previously described [11, 20, 21].
Cardiac monitoring
The performance of physical examinations, an 
ECG, and an assessment of LVEF by echocardiography 
or MUGA scanning were planned at baseline and every 
9–12 weeks during first line treatment. An additional 
cardiologic workup was conducted when the patients 
complained of cardiologic symptoms including chest pain, 
chest discomfort, or dyspnea on exertion.
Definitions
In this study, cardiac dysfunction included a 
significant drop in LVEF, severe CHF, and cardiac death. 
A significant drop in LVEF was defined as an absolute 
decline of at least 10 percentage points from the baseline 
to a value less than 55% identified by a MUGA scan or 
echocardiogram regardless of symptoms, which were 
defined in a previous study [8]. Severe CHF was defined 
as class III or IV according to the New York Heart 
Association (NYHA) with a significant drop in LVEF [22]. 
Cardiac death was defined as death that was definitively 
due to heart failure, myocardial infarction, or primary 
arrhythmia. Cardiac dysfunction related to treatment 
with trastuzumab was defined as trastuzumab-induced 
cardiotoxicity (TIC). Abnormal results were analyzed for 
up to three months from the date of the last administration 
of trastuzumab. The definition of reversibility was 
in accord with an expert consensus suggested by the 
American Society of Echocardiography [23].
Statistical analysis
The clinical differences between the groups that 
received first-line chemotherapy with or without HER2-
targeted therapy were analyzed using the Chi-square, 
Fisher’s exact, and Mann-Whitney U tests. Cumulative 
incidences of cardiac dysfunction were compared using 
a Kaplan-Meier analysis. The incidence of cardiac 
dysfunction between each of the groups with different 
clinicopathological features was compared using logistic 
regression models. A P <0.05 was considered statistically 
significant. All statistical analyses were performed using 
Oncotarget61844www.impactjournals.com/oncotarget
IBM SPSS version 23.0 for Windows (IBM, Armonk, NY, 
USA).
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